Outcome of very young (≤40 years) patients with immunoglobulin light chain (AL) amyloidosis

Amyloid. 2017 Mar;24(sup1):50-51. doi: 10.1080/13506129.2017.1286584.

Authors

Jithma P Abeykoon¹, Jonas Paludo^{1

2}, Angela Dispenzieri^{1

2}, Morie A Gertz^{1

2}, David Dingli^{1

2}, Francis K Baudi^{1

2}, Wilson I Gonsalves^{1

2}, Robert A Kyle^{1

2}, Martha Q Lacy^{1

2}, Suzanne R Hayman^{1

2}, Nelson Leung^{1

2}, Taxiarchis Kourelis^{1

2}, S Vincent Rajkumar^{1

2}, Shaji Kumar^{1

2}, Prashant Kapoor^{1

2}

Affiliations

¹ a Department of Internal Medicine and.
² b Division of Hematology , Mayo Clinic , Rochester , MN , USA.

PMID: 28434368
DOI: 10.1080/13506129.2017.1286584

No abstract available

Publication types

Letter

MeSH terms

Adult
Combined Modality Therapy
Female
Humans
Immunoglobulin Light-chain Amyloidosis / mortality*
Immunoglobulin Light-chain Amyloidosis / therapy
Male
Prognosis
Severity of Illness Index
Survival Rate